Skip to main content
. 2019 Jun 27;3(13):1930–1938. doi: 10.1182/bloodadvances.2018028530

Figure 1.

Figure 1.

Survival outcomes in patients with de novo del(17p), acquired del(17p), and controls. (A) Comparison of PFS in the 3 groups: 21.2 months (95% CI, 17.8-23.9) vs 23.0 months (95% CI, 20.2-27.8) vs 30.1 months (95% CI, 26.0-33.9). *P = .032 for acquired del(17p) vs controls; **P = .887 for acquired del(17p) vs de novo del(17p). (B) Comparison of OS from diagnosis in the 3 groups: 47.3 months (95% CI, 42.7-55.9) vs 68.2 months (95% CI, 50.8-74.8) vs 106.1 months (95%CI, 101.6-119.4). *P < .001 for acquired del(17p) vs controls; **P = .063 for acquired del(17p) vs de novo del(17p).